
Cantargia Q3 2022 - Focus on Randomised Trials

Redeye comments on Cantargia's third quarter report and events after the end of the quarter, including the decision to pause three trials.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Cantargia Q3 2022 - Focus on Randomised Trials](#)